2. Academic Validation
  3. Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders

Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders

  • J Med Chem. 2025 Feb 13;68(3):2608-2638. doi: 10.1021/acs.jmedchem.4c01787.
Yanqing Zhang 1,  Wenjing Liu 2,  Chao Tong 1,  Xinhong Wang 2,  Xiujin Chang 1,  Fangui Qu 1,  Zhiming Zhang 1,  Zhongpen Fan 1,  Monong Zhao 1,  Cheng Tang 1,  Beichen Song 3,  Ming Ding 3,  Zhixia Qiu 2,  Jubo Wang 1,  Jinlei Bian 1,  Zhiyu Li 1,  Hongxi Wu 2,  Xi Xu 1
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211100, P. R. China.
  • 2 Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, P. R. China.
  • 3 School of Life Science and Technology, China Pharmaceutical University, Nanjing 211100, P. R. China.
PMID: 39854008 DOI: 10.1021/acs.jmedchem.4c01787
Abstract

Molecular glue degraders induce "undruggable" protein degradation by a proximity-induced effect. Inspired by the clinical success of immunomodulatory drugs, we aimed to design novel molecular glue degraders targeting GSPT1. Here, we report the design of a series of GSPT1 molecular glue degraders. LYG-409, a 2H-chromene derivative, was identified as a potent, selective, and orally bioavailable GSPT1 degrader with excellent antitumor activity in vivo (anti-Acute Myeloid Leukemia MV4-11 xenograft model: TGI = 94.34% at 30 mg/kg; prostate Cancer 22Rv1 xenograft model: TGI = 104.49% at 60 mg/kg) and in vitro (KG-1 cells: IC50 = 9.50 ± 0.71 nM, DC50 = 7.87 nM) mediated by the degradation of GSPT1. In conclusion, LYG-409 exhibits potent GSPT1 degradation activity, demonstrating promising therapeutic efficacy and favorable safety profile. However, its potential drug resistance profile needs to be thoroughly evaluated in comparison with existing treatments. We hope LYG-409 can provide a valuable direction for the development of GSPT1 degraders.

Figures
Products